(SOURCE: UNIVERSITY OF MANCHESTER) – A new combination of drugs, tested by University of Manchester scientists, has significantly enhanced the survival of laboratory mice with lymphoma. According to the team, the effect of Obinutuzumab – a first-line treatment for non-Hodgkin lymphoma and leukaemia – is significantly enhanced when combined with drugs that stimulate the immune system. […]
(SOURCE: H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE) – Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors. The body has two types of lymphocytes that can develop into lymphoma – B cells and T […]
(SOURCE: NIH/NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES) – Immune Molecule Deficiency Increases Patients’ Risk of Epstein-Barr Virus and EBV-Related Cancer. Investigators at the National Institutes of Health (NIH) and international colleagues have identified a genetic immune disorder characterized by increased susceptibility and poor immune control of Epstein-Barr virus (EBV) and, in some cases, an EBV-associated cancer […]
(SOURCE: MAYO CLINIC) – Mayo Clinic has created a genetic test to help guide diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma. The Lymph2Cx test helps determine where the lymphoma started, assigning “cell-of-origin” groups using a 20-gene expression-based assay. It is the first test to go into […]
(SOURCE: DANA-FARBER CANCER INSTITUTE) – An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with either of two rare, aggressive forms of non-Hodgkin lymphoma, results from a small case series indicate. Dana-Farber Cancer Institute investigators who treated the patients will report their findings at the 58th annual meeting […]
(SOURCE: DANA-FARBER CANCER INSTITUTE) – A significant percentage of lymphoma patients undergoing transplants with their own blood stem cells carry acquired genetic mutations that increase their risks of developing second hematologic cancers and dying from other causes, according to a study from Dana-Farber Cancer Institute. The mutations were found in about 30 percent of 401 patients with […]
(SOURCE: AMERICAN SOCIETY OF HEMATOLOGY) Interim analysis shows nearly six-fold higher rate of complete remission for refractory non-Hodgkin lymphoma with KTE-C19 compared to historical data. An abstract presented during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for […]
(Stanford) According to a recently published article, monitoring cancer DNA in blood can predict recurrence and prognosis and drive treatment decisions. A Stanford study of 92 lymphoma patients suggests similar techniques may work for other tumors.
(UNIVERSITY OF SUSSEX) According to a recent press release, scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.
(Scientific American) According to an article recently published in Scientific American, a team of researchers from California and Japan has found that an essential amino acid plays a crucial role in the creation of blood stem cells. This type of discovery the scientists say could offer a potential alternative to chemotherapy and radiation in treating […]
(SBS Australia) According to an article recently published on SBS, a team of international researchers at Australia’s Walter and Eliza Hall Institute have made a “major scientific breakthrough” in cancer research that has the potential to help millions of people with the deadly disease.
(Healio) According to an article recently published in Healio, patients with HIV who receive antiretroviral therapy are at a higher risk for developing non-Hodgkin’s lymphoma if they are infected with both hepatitis B and C viruses, according to study findings published in Annals of Internal Medicine.
(Lymphona News Today) According to an article recently published in Lymphoma News Today, The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that Opdivo (nivolumab) be approved for the treatment of classical Hodgkin’s lymphoma (cHL) in patients who relapsed or progressed after receiving an autologous stem cell transplant (ASCT) and Adectris (brentuximab vedotin) treatment.
(US National Library of Medicine) According to a recent study published in The Lancet Oncology, patients with Hodgkin’s lymphoma might have persistent fatigue even years after treatment. However, knowledge of the development of fatigue persisting long after completion of treatment is limited. The research study involved a detailed analysis of fatigue in first-line clinical trials for […]